Imaging tau protein in the brain using a new PET scan technique
Clinical Study of [18F] PM-PBB3 PET Imaging of Tau Protein in Neurodegenerative Diseases
This study is testing a new PET scan technique to see if it can better show tau protein changes in the brains of people with neurodegenerative diseases.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 49 Years to 80 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06344845 on ClinicalTrials.gov |
What this trial studies
This clinical study aims to evaluate the effectiveness of the [18F] PM-PBB3 PET imaging technique for visualizing tau protein abnormalities in patients with neurodegenerative diseases. The study involves administering a positron tracer that binds specifically to tau protein, allowing for enhanced imaging quality and broader clinical applications compared to previous agents. Participants will undergo a PET/CT scan to assess the distribution of tau protein in the brain, which could aid in the diagnosis and understanding of neurodegenerative conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 45 to 90 with a confirmed diagnosis of neurodegeneration and no other neurological disorders.
Not a fit: Patients with serious neurological disorders or those unwilling to undergo PET/CT scans may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve diagnostic accuracy for neurodegenerative diseases by providing clearer imaging of tau protein abnormalities.
How similar studies have performed: Other studies have explored tau imaging techniques, but the specific use of [18F] PM-PBB3 is a novel approach that has not been widely tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Between 45 and 90 years old; No gender limitation. Brain MRI supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases. Informed consent signed in person by the subject or his legal guardian or caregiver. Exclusion Criteria: * Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases. Received an experimental drug or device within 1 month (whose efficacy or safety is unclear). patients who were unwilling to undergo PET/CT scans. pregnancy.
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Ruixue Cui, M.D. — Peking Union Medical College Hospital
- Study coordinator: Chenhao Jia, M.D.
- Email: jiachenhao24@163.com
- Phone: 86+18548703382
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.